What is it about?
9 General Practitioners (GP) from the Rome area (Italy) performed a retrospective analysis in order to evaluate the role of the supplementation with Palmitoylethanolamide (PEA) co-ultramicronized with Luteolin (PEALUT) on neurologic and clinical symptoms reported by their patients after COVID-19 resolution (Long Covid Syndrome: LCS). The presence and distribution of the assessed clinical symptoms such as anosmia, dysgeusia, brain fog, difficulty multitasking, fatigue, irritability, inability to find the right word, memory loss and weakness, significantly improved during the treatment period.
Featured Image
Photo by JJ Ying on Unsplash
Why is it important?
To our knowledge these are the first data presented on LCS patients, not previously hospitalized, collected in a territorial setting. It is noteworthy that the doctor–patient relationship, characterized by a familiar approach (less delayed by logistical and bureaucratic disadvantages), allowed the early identification of Long COVID patients, which allowed us to counteract the neuroinflammatory process in its initial phase. Despite their preliminary nature, these results highlight the pathogenetic role of “non-resolving” neuroinflammation in LCS development and consequently the importance of its control in the resolution of the pathology and put the focus on the GP as the primary figure for early detection and management of LCS in a real-life setting.
Perspectives
A recent review published on Nature reported that at least 65 million people worldwide have already experienced this pathology [4] and projections of the most authoritative scientific literature estimate that LCS will affect in the future more than 200 million people, mainly between 20 and 50 years old. The first “landing point” for many patients is usually their GP, from whom they need confidence, empathy and understanding and whose support, during recovery and rehabilitation from COVID-19, is even more essential. This suggests that, at least in the prodromal phases, the GP could be the most appropriate figure in the territorial setting for the management of LCS. This approach, if validated, could represent an alternative or a complementary model to hospital care (of which timing for treatment is delayed and less comfortable both in interpersonal and logistical aspects) and also more sustainable for the entire health system. Furthermore, for a lot of reasons, it becomes crucial to find new approaches to control as early as possible the neuroinflammatory process acting on the immune system regulation. .From this perspective, a putative intervention might be represented by PEALUT.
Prof. Maurizio Evangelista
Universita Cattolica del Sacro Cuore
Read the Original
This page is a summary of: What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life Setting, Nutrients, August 2023, MDPI AG,
DOI: 10.3390/nu15173701.
You can read the full text:
Contributors
The following have contributed to this page
